Northern Trust’s Impact BioMedical IBO Stock Holding History

Northern Trust’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$146K	Buy	243,943 +233,718	+2,286%	+$117K	﹤0.01%	4026
2025 Q4	$5.16K	Buy	+10,225	New	+$5.41K	﹤0.01%	4446

Other funds holding IBO

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VGA

Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

MAC

Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust's IBO Position: Q1 2026 in Review

Northern Trust increased its Impact BioMedical (IBO) stake by 2,286% in Q1 2026, buying an estimated $117K and bringing the position to 243,943 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #4026.

Northern Trust first reported a position in IBO in Q4 2025 and has held it in 2 quarters since. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

Northern Trust held 243,943 shares of Impact BioMedical worth $146K as of Q1 2026.
Northern Trust bought 233,718 Impact BioMedical shares in Q1 2026, an estimated $117K.
Impact BioMedical made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4026 holding.
Northern Trust first reported a position in Impact BioMedical in Q4 2025 and has held it in 2 quarters since.
20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.